JP2010520758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010520758A5 JP2010520758A5 JP2009552983A JP2009552983A JP2010520758A5 JP 2010520758 A5 JP2010520758 A5 JP 2010520758A5 JP 2009552983 A JP2009552983 A JP 2009552983A JP 2009552983 A JP2009552983 A JP 2009552983A JP 2010520758 A5 JP2010520758 A5 JP 2010520758A5
- Authority
- JP
- Japan
- Prior art keywords
- reovirus
- nucleic acid
- residue
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000702263 Reovirus sp. Species 0.000 claims 69
- 229920001184 polypeptide Polymers 0.000 claims 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- 150000007523 nucleic acids Chemical class 0.000 claims 38
- 230000004048 modification Effects 0.000 claims 35
- 238000012986 modification Methods 0.000 claims 35
- 108020004707 nucleic acids Proteins 0.000 claims 29
- 102000039446 nucleic acids Human genes 0.000 claims 29
- 230000001965 increasing effect Effects 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 150000001413 amino acids Chemical class 0.000 claims 16
- 238000000034 method Methods 0.000 claims 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 9
- 102100037651 AP-2 complex subunit sigma Human genes 0.000 claims 4
- 101000806914 Homo sapiens AP-2 complex subunit sigma Proteins 0.000 claims 4
- 108700034660 Reovirus lambda3 Proteins 0.000 claims 4
- 230000006037 cell lysis Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000035945 sensitivity Effects 0.000 claims 4
- 238000001959 radiotherapy Methods 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 241000725641 Reovirus S4 Species 0.000 claims 2
- 108700018523 Reovirus mu2 Proteins 0.000 claims 2
- 108700023681 Reovirus sigma NS Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 230000004900 autophagic degradation Effects 0.000 claims 2
- 230000008901 benefit Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 230000008406 drug-drug interaction Effects 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 230000005847 immunogenicity Effects 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000017074 necrotic cell death Effects 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 230000007505 plaque formation Effects 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 241000702244 Orthoreovirus Species 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000002650 immunosuppressive therapy Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000002703 mutagenesis Methods 0.000 claims 1
- 231100000350 mutagenesis Toxicity 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000002741 site-directed mutagenesis Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89442507P | 2007-03-12 | 2007-03-12 | |
| US60/894,425 | 2007-03-12 | ||
| US98956807P | 2007-11-21 | 2007-11-21 | |
| US60/989,568 | 2007-11-21 | ||
| PCT/CA2008/000483 WO2008110004A1 (en) | 2007-03-12 | 2008-03-11 | Reoviruses having modified sequences |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010520758A JP2010520758A (ja) | 2010-06-17 |
| JP2010520758A5 true JP2010520758A5 (enExample) | 2011-04-28 |
| JP5577103B2 JP5577103B2 (ja) | 2014-08-20 |
Family
ID=39758956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009552983A Active JP5577103B2 (ja) | 2007-03-12 | 2008-03-11 | 改変配列を有するレオウイルス |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US7803385B2 (enExample) |
| EP (2) | EP2952583A1 (enExample) |
| JP (1) | JP5577103B2 (enExample) |
| KR (1) | KR101647843B1 (enExample) |
| CN (1) | CN103710359A (enExample) |
| AR (1) | AR066395A1 (enExample) |
| AU (1) | AU2008226291B2 (enExample) |
| CA (1) | CA2678721C (enExample) |
| DK (1) | DK2132315T3 (enExample) |
| ES (1) | ES2548442T3 (enExample) |
| IL (4) | IL200353A (enExample) |
| MX (2) | MX2009009598A (enExample) |
| SG (1) | SG191602A1 (enExample) |
| TW (1) | TW200904979A (enExample) |
| WO (1) | WO2008110004A1 (enExample) |
| ZA (1) | ZA200905951B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| DK2132315T3 (en) | 2007-03-12 | 2015-10-19 | Oncolytics Biotech Inc | Reoviruses with modified sequences |
| JP2011500608A (ja) * | 2007-10-22 | 2011-01-06 | オンコリティクス バイオテク，インコーポレーテッド | 増殖性障害の治療レジメン |
| CA2723587C (en) * | 2008-05-27 | 2017-09-26 | Oncolytics Biotech Inc. | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy |
| MX339014B (es) * | 2008-05-27 | 2016-05-09 | Oncolytics Biotech Inc | Modulacion de presion intersticial y suministro y distribucion viral oncolitica. |
| BRPI0910185A2 (pt) * | 2008-06-26 | 2015-12-01 | Ceva Sante Animale S A | sorotipo de reovírus aviário isolado, reovírus aviário isolado, peptídeos, vacina, antisoro isolado, anticorpo isolado, método para proteção de aves, método para detecção ou quantificação de reovírus em aves, recipiente para vacinação de aves, kit para vacinação de aves, kit de diagnóstico, linhagem celular derivada da lmh |
| FR2939807B1 (fr) * | 2008-12-11 | 2010-12-17 | Biomerieux Sa | Nouveau reovirus isole, procedes et kits de detection |
| US9395356B2 (en) * | 2009-10-02 | 2016-07-19 | The National Veterinary Institute | Piscine reovirus immunogenic compositions |
| ES2630012T3 (es) | 2010-12-02 | 2017-08-17 | Oncolytics Biotech Inc. | Formulaciones virales liofilizadas |
| EA201390810A1 (ru) * | 2010-12-02 | 2013-09-30 | Онколитикс Байотек Инк. | Жидкие вирусные составы |
| ES2822199T3 (es) * | 2011-04-29 | 2021-04-29 | Oncolytics Biotech Inc | Métodos de purificación de virus usando cromatografía por permeación en gel |
| EP3068411B1 (en) * | 2013-11-15 | 2020-03-18 | Oncolytics Biotech Inc. | Oncolytic viruses and increased cancer treatment regimens |
| US9660989B1 (en) | 2014-01-31 | 2017-05-23 | Google Inc. | Internet-wide identity management widget |
| AU2017221592A1 (en) | 2016-02-16 | 2018-10-04 | Osaka University | Pharmaceutical composition for use in treating fibrosis |
| WO2019237063A1 (en) * | 2018-06-07 | 2019-12-12 | Emory University | Modified reoviruses, particles, and uses in treating proliferative disorders |
| KR102401077B1 (ko) | 2019-01-25 | 2022-05-24 | 바이로큐어 주식회사 | 다람쥐 섬유종 바이러스 및 리오바이러스를 포함하는 암 예방 또는 치료용 약학적 조성물 |
| US20220193220A1 (en) * | 2019-05-03 | 2022-06-23 | Kansas State University Research Foundation | Immunogenic compositions for novel reassortant mammalian ortheovirus from pigs |
| KR20220090467A (ko) * | 2020-12-22 | 2022-06-29 | 바이로큐어 주식회사 | 신규한 변형 레오바이러스 및 이의 용도 |
| US20240041959A1 (en) * | 2020-12-22 | 2024-02-08 | Virocure, Inc. | Novel modified reovirus and use thereof |
| US20250154204A1 (en) * | 2021-09-24 | 2025-05-15 | Virocure, Inc. | Novel reovirus-based vaccine platform and use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US6565831B1 (en) | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| TWI289158B (en) * | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
| CA2428206C (en) * | 2000-11-09 | 2005-09-27 | Oncolytics Biotech Inc. | Methods for the treatment of cellular proliferative disorders |
| WO2002043647A2 (en) | 2000-12-01 | 2002-06-06 | University Of Ottawa | Oncolytic virus |
| JP4087712B2 (ja) * | 2001-03-16 | 2008-05-21 | オンコリティクス バイオテック， インコーポレイティッド | 細胞培養物からウイルスを抽出する方法 |
| US7163678B2 (en) * | 2002-11-07 | 2007-01-16 | Oncolytics Biotech Inc. | Reovirus for the treatment of ral-mediated cellular proliferative disorders |
| WO2005111200A1 (en) * | 2004-05-17 | 2005-11-24 | Universite De Montreal | Novel strains of reoviruses and methods of uses thereof |
| CA2571849A1 (en) * | 2004-06-24 | 2006-01-05 | Dnavec Research Inc. | Anticancer agent containing dendritic cell having rna virus transferred thereinto |
| US10260049B2 (en) * | 2005-08-01 | 2019-04-16 | Virocure, Inc. | Attenuated reovirus |
| US20100086522A1 (en) | 2006-07-18 | 2010-04-08 | Ottawa Health Research Institute | Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses |
| DK2132315T3 (en) * | 2007-03-12 | 2015-10-19 | Oncolytics Biotech Inc | Reoviruses with modified sequences |
| CA2723587C (en) * | 2008-05-27 | 2017-09-26 | Oncolytics Biotech Inc. | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy |
| ES2630012T3 (es) * | 2010-12-02 | 2017-08-17 | Oncolytics Biotech Inc. | Formulaciones virales liofilizadas |
| EA201390810A1 (ru) * | 2010-12-02 | 2013-09-30 | Онколитикс Байотек Инк. | Жидкие вирусные составы |
-
2008
- 2008-03-11 DK DK08733587.3T patent/DK2132315T3/en active
- 2008-03-11 WO PCT/CA2008/000483 patent/WO2008110004A1/en not_active Ceased
- 2008-03-11 ES ES08733587.3T patent/ES2548442T3/es active Active
- 2008-03-11 EP EP15176066.7A patent/EP2952583A1/en not_active Withdrawn
- 2008-03-11 US US12/046,095 patent/US7803385B2/en active Active
- 2008-03-11 KR KR1020097019418A patent/KR101647843B1/ko active Active
- 2008-03-11 JP JP2009552983A patent/JP5577103B2/ja active Active
- 2008-03-11 EP EP08733587.3A patent/EP2132315B1/en active Active
- 2008-03-11 CN CN201310353609.2A patent/CN103710359A/zh active Pending
- 2008-03-11 CA CA2678721A patent/CA2678721C/en active Active
- 2008-03-11 SG SG2013040027A patent/SG191602A1/en unknown
- 2008-03-11 MX MX2009009598A patent/MX2009009598A/es active IP Right Grant
- 2008-03-12 TW TW097108636A patent/TW200904979A/zh unknown
- 2008-03-12 AR ARP080101017A patent/AR066395A1/es unknown
- 2008-03-14 AU AU2008226291A patent/AU2008226291B2/en active Active
-
2009
- 2009-08-12 IL IL200353A patent/IL200353A/en active IP Right Grant
- 2009-08-27 ZA ZA2009/05951A patent/ZA200905951B/en unknown
- 2009-09-08 MX MX2013013938A patent/MX346950B/es unknown
-
2010
- 2010-08-02 US US12/848,684 patent/US8691241B2/en active Active
-
2012
- 2012-08-30 IL IL221702A patent/IL221702A0/en unknown
- 2012-08-30 IL IL221700A patent/IL221700A0/en unknown
- 2012-08-30 IL IL221701A patent/IL221701A0/en unknown
-
2014
- 2014-02-13 US US14/179,840 patent/US10039827B2/en active Active
-
2018
- 2018-07-03 US US16/027,206 patent/US10596260B2/en active Active
-
2020
- 2020-02-13 US US16/790,114 patent/US11246930B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010520758A5 (enExample) | ||
| JP5577103B2 (ja) | 改変配列を有するレオウイルス | |
| AU782020B2 (en) | Viruses for the treatment of cellular proliferative disorders | |
| CN102858959B (zh) | 溶瘤弹状病毒 | |
| JP7564572B2 (ja) | 単離された組換え体腫瘍溶解性ワクシニアウイルスとｎｋ細胞を含む治療薬、その使用およびそれを適用したキット | |
| Bourke et al. | The emerging role of viruses in the treatment of solid tumours | |
| Sinkovics et al. | Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers | |
| CA2494844A1 (en) | Methods and compositions concerning poxviruses and cancer | |
| JP7239910B2 (ja) | 治療剤、ならびに腫瘍および／またはがんの治療のための薬物のためのその使用 | |
| WO2018058258A1 (en) | Recombinant oncolytic viruses for cancer therapy | |
| CN101679953A (zh) | 突变的呼肠孤病毒及其制备和使用方法 | |
| JP7144915B2 (ja) | 腫瘍を治療するためのウイルス | |
| CN119709652A (zh) | 溶瘤病毒及其应用 | |
| AU2014292114B2 (en) | Genetically stable oncolytic RNA virus, method of manufacturing and use thereof | |
| JP7336791B2 (ja) | 腫瘍を治療するためのコクサッキーウイルスｂ群 | |
| US20200199624A1 (en) | Recombinant oncolytic virus | |
| US20220296659A1 (en) | Pharmaceutical composition for treatment of tumor or cancer, and application thereof | |
| WO2020238427A1 (zh) | 特异杀伤肿瘤细胞的溶瘤病毒系统及其应用 | |
| AU2009253683B2 (en) | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy | |
| Mohamadi et al. | The important role of oncolytic viruses in common cancer treatments | |
| US20240318147A1 (en) | Recombinant oncolytic virus, and construction method therefor and use thereof | |
| WO2019174610A1 (zh) | 一种溶瘤病毒、合成dna序列及其应用 | |
| WO2022245808A1 (en) | Oncolytic virus based cancer therapy | |
| CN120789239A (zh) | 重组溶瘤病毒和单克隆抗体联用在制备用于治疗hbv阳性肝癌的药物中的应用 | |
| Roussy | 252. Complete Melanoma Regressions after Electrotransfer of the p-AMEP™ Plasmid Coding for an Anti-Angiogenic and Anti-Metastatic Peptide |